Comparative Pharmacology
Head-to-head clinical analysis: ATENOLOL versus CARVEDILOL PHOSPHATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ATENOLOL versus CARVEDILOL PHOSPHATE.
ATENOLOL vs CARVEDILOL PHOSPHATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective beta-1 adrenergic receptor antagonist; reduces heart rate, myocardial contractility, and blood pressure by blocking catecholamine effects.
Competitive beta-blocker with alpha1-blocking activity; decreases cardiac output, reduces peripheral vascular resistance.
50 mg orally once daily; may increase to 100 mg orally once daily if needed.
6.25 mg orally twice daily, titrated up to a maximum of 25 mg twice daily for heart failure; 12.5 mg orally once daily for hypertension, titrated to 25-50 mg daily.
None Documented
None Documented
6-9 hours (terminal elimination half-life); may increase to 15-30 hours in renal impairment (CrCl <35 mL/min).
Clinical Note
moderateAtenolol + Digoxin
"Atenolol may increase the bradycardic activities of Digoxin."
Clinical Note
moderateAtenolol + Digitoxin
"Atenolol may increase the bradycardic activities of Digitoxin."
Clinical Note
moderateAtenolol + Deslanoside
"Atenolol may increase the bradycardic activities of Deslanoside."
Clinical Note
moderateAtenolol + Acetyldigitoxin
"Atenolol may increase the bradycardic activities of Acetyldigitoxin."
7-10 hours (terminal elimination half-life); clinical context: supports twice-daily dosing for sustained beta-blockade.
Renal: 40-50% unchanged drug; minor hepatic metabolism (10-20%) with biliary excretion of metabolites; <5% fecal.
Primarily hepatic metabolism (CYP2D6 and CYP2C9) followed by biliary excretion into feces; ~60% fecal elimination as metabolites, ~16% renal elimination of unchanged drug plus metabolites.
Category C
Category C
Beta-Blocker
Alpha/Beta-Blocker